SYNTAX is breaking new ground by scientifically defining a new measure for anatomical complexity - the SYNTAX Score - which seeks to provide guidance to physicians on optimal treatment options for this high-risk group of patients. The SYNTAX Score characterizes vasculature based on lesion frequency, complexity and location, relying on data from the SYNTAX trial as well as information collected through other sources.
The safety and effectiveness of the TAXUS Express2 Stent System has not been established in patients with left main or three-vessel disease.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward- looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding clinical trials, regulatory approvals, competitive offerings and
product performance. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together w
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved